바이오테크 보도자료
-
- Takeda’s Pipeline Has Potential to Contribute Significantly to Revenue Growth Over Next Decade
- As part of its Wave 1 Pipeline Market Opportunity Call, Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) provided an update on its pipeline portfolio, which has the potential to contribute significantly to revenue growth for th...
- 2020년 12월 11일
-
- Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates
- Boehringer Ingelheim today announced the signing of a binding agreement for acquiring all shares of NBE-Therapeutics, a private, clinical-stage Swiss biotechnology company focused on antibody-drug conjugates and advancing targeted cancer therapies...
- 2020년 12월 11일
-
- GLEIF Advances Digital Trust and Identity for Legal Entities Globally
- The Global Legal Entity Identifier Foundation (GLEIF) is to extend the Global LEI System to create a fully digitized LEI service capable of enabling instant and automated identity verification between counterparties operating across all industry s...
- 2020년 12월 11일
-
- Takeda Presents Real-World Evidence at ASH 2020, Demonstrating Its Long-Standing Commitment to Personalizing Treatments for Rare Bleeding Disorders
- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”), today presented five hematology poster presentations and four abstracts at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition that underscore its commitm...
- 2020년 12월 10일
-
- PMC Organometallix Continues Expansion
- PMC Organometallix Inc., a wholly owned subsidiary of PMC Group N.A., Inc. is pleased to confirm that, despite challenges presented by the global pandemic, it has embarked on, and will continue with plans to expand capacity for production of organ...
- 2020년 12월 10일
-
- Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program
- Boehringer Ingelheim today announced the execution of the agreement on the acquisition of Labor Dr. Merk & Kollegen. The acquisition will enable Boehringer Ingelheim to further expand and accelerate its comprehensive program for the development of...
- 2020년 12월 10일
-
- Takeda Announces Approval of TAKHZYRO® (lanadelumab) subcutaneous injection in China for the Treatment of Hereditary Angioedema
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that China’s National Medical Products Administration (NMPA) has approved TAKHZYRO® (lanadelumab) subcutaneous injection for prophylaxis to prevent attacks of her...
- 2020년 12월 08일
-
- Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders - a Novel Approach to Fight Cancer
- Boehringer Ingelheim and Proxygen today announced they have entered into a collaboration and license agreement to enable the identification of molecular glue degraders against various oncogenic targets. The collaboration combines Proxygen’s unique...
- 2020년 12월 08일
-
- GenesisCare Clinical CRO Adopts Veeva Vault Clinical Applications to Accelerate and Scale Studies Globally
- Veeva Systems (NYSE: VEEV) today announced that contract research organisation (CRO) GenesisCare Clinical CRO, founded by GenesisCare, has adopted Veeva Vault eTMF, Veeva Vault CTMS, and Veeva Vault Payments to drive efficient trial processes glob...
- 2020년 12월 07일
-
- Rhizen Pharmaceuticals SA Announces Presentation of the Interim Results of the Phase I/II study of Tenalisib (RP6530) in Combination with Romidepsin in Relapsed/Refractory T-cell Lymphoma at American Society of Hematology (ASH) annual meeting, 2020
- Rhizen Pharmaceuticals, a clinical-stage oncology-focussed biopharmaceutical company, today announced presentation of the interim results of a Phase I/II combination study of Tenalisib with Romidepsin for relapsed/refractory T-Cell Lymphoma patien...
- 2020년 12월 07일
-
- New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus (CMV) Infections, Meets Primary Endpoint
- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced top-line results from the Phase 3 clinical trial evaluating the efficacy and safety of the investigational drug TAK-620 (maribavir), in the treatment of transplan...
- 2020년 12월 07일
-
- Shape Therapeutics Unveils AAVid™ Capsid Discovery Platform and Identification of Novel Tissue-Specific AAV Variants, Solving a Fundamental Delivery Challenge in Gene Therapy
- Shape Therapeutics, Inc. (ShapeTX), a next-generation gene therapy company with an industry-leading RNA targeting technology platform, announces today the unveiling of the AAVidTM capsid discovery platform and results from its first AAV5 variant l...
- 2020년 12월 04일
전시회
